AU2015254865B2 - Administration of citicoline to improve cognitive performance, attentional performance, and motor function - Google Patents

Administration of citicoline to improve cognitive performance, attentional performance, and motor function Download PDF

Info

Publication number
AU2015254865B2
AU2015254865B2 AU2015254865A AU2015254865A AU2015254865B2 AU 2015254865 B2 AU2015254865 B2 AU 2015254865B2 AU 2015254865 A AU2015254865 A AU 2015254865A AU 2015254865 A AU2015254865 A AU 2015254865A AU 2015254865 B2 AU2015254865 B2 AU 2015254865B2
Authority
AU
Australia
Prior art keywords
day
visit
group
placebo
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015254865A
Other languages
English (en)
Other versions
AU2015254865A1 (en
Inventor
Takeshi Ikeda
Masahiko Morita
Perry Renshaw
Miho Takada
Deborah Yurgelun-Todd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of AU2015254865A1 publication Critical patent/AU2015254865A1/en
Application granted granted Critical
Publication of AU2015254865B2 publication Critical patent/AU2015254865B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2015254865A 2014-04-30 2015-04-30 Administration of citicoline to improve cognitive performance, attentional performance, and motor function Active AU2015254865B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986502P 2014-04-30 2014-04-30
US61/986,502 2014-04-30
PCT/IB2015/053178 WO2015166463A1 (en) 2014-04-30 2015-04-30 Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Publications (2)

Publication Number Publication Date
AU2015254865A1 AU2015254865A1 (en) 2016-11-24
AU2015254865B2 true AU2015254865B2 (en) 2020-07-02

Family

ID=54358252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015254865A Active AU2015254865B2 (en) 2014-04-30 2015-04-30 Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Country Status (8)

Country Link
US (2) US11583546B2 (enExample)
EP (1) EP3137067B1 (enExample)
JP (1) JP6584430B2 (enExample)
AU (1) AU2015254865B2 (enExample)
CA (1) CA2947252C (enExample)
ES (1) ES2915909T3 (enExample)
PL (1) PL3137067T3 (enExample)
WO (1) WO2015166463A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2014069667A1 (en) * 2012-10-30 2014-05-08 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
EP1604671A4 (en) * 2003-02-26 2006-03-29 Kyowa Hakko Kogyo Kk MUSCLE TREATMENT AND MEANS FOR PREVENTING OR TREATING MUSCLE WEAKNESS
US20070248696A1 (en) * 2006-04-25 2007-10-25 Mind Sports Nutrition Inc. Composition and method for enhancing neuromuscular facilitation and cognitive functions
US20100041620A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods for improving frontal brain bioenergetic metabolism
US9883831B1 (en) * 2014-01-30 2018-02-06 Texas Health Biomedical Advancement Center, Inc. Digital medical evaluation and testing on a touch screen device
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2014069667A1 (en) * 2012-10-30 2014-05-08 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. M. SILVERI, J. DIKAN, A. J. ROSS, J. E. JENSEN, T. KAMIYA, Y. KAWADA, P. F. RENSHAW, D. A. YURGELUN-TODD: "Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy", NMR IN BIOMEDICINE., WILEY, LONDON., GB, vol. 21, no. 10, 1 December 2008 (2008-12-01), GB, pages 1066 - 1075, XP055234021, ISSN: 0952-3480, DOI: 10.1002/nbm.1281 *
STEVEN E. BRUCE, "Improvements in quantitative EEG following consumption of a natural citicoline-enhanced beverage", Int J Food Sci Nutr., (2012), vol. 63, no. 4, pages 421 - 5 *

Also Published As

Publication number Publication date
US12115181B2 (en) 2024-10-15
CA2947252A1 (en) 2015-11-05
CA2947252C (en) 2022-05-10
US20230181614A1 (en) 2023-06-15
JP6584430B2 (ja) 2019-10-02
PL3137067T3 (pl) 2022-06-27
EP3137067A4 (en) 2017-12-27
JP2017520513A (ja) 2017-07-27
EP3137067A1 (en) 2017-03-08
NZ725643A (en) 2021-08-27
EP3137067B1 (en) 2022-05-04
WO2015166463A1 (en) 2015-11-05
AU2015254865A1 (en) 2016-11-24
ES2915909T3 (es) 2022-06-27
US11583546B2 (en) 2023-02-21
US20170049796A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
Wortman et al. 19 Beyond the Myths of Coping with Loss: Prevailing Assumptions Versus Scientific Evidence
Murphy et al. Emotion modulates cognitive flexibility in patients with major depression
Bartholow et al. Effects of alcohol consumption and alcohol susceptibility on cognition: a psychophysiological examination
Hoppe et al. Epilepsy: accuracy of patient seizure counts
Anguera et al. Video game training enhances cognitive control in older adults
Kraus et al. Cognition as an outcome measure in schizophrenia
Compton et al. Responding to threat: hemispheric asymmetries and interhemispheric division of input.
Dickstein et al. Neuropsychological performance in pediatric bipolar disorder
Podell et al. Neuropsychological assessment in traumatic brain injury
Brazil et al. A neurophysiological dissociation between monitoring one's own and others' actions in psychopathy
Karsz et al. Olfactory impairments in child attention-deficit/hyperactivity disorder.
Luborsky et al. A context analysis of psychological states prior to petit mal EEG paroxysms
Crosswell et al. Effects of acute stress on cognition in older versus younger adults.
Schmitt et al. Age-differential effects on updating cue information: Evidence from event-related potentials
US12115181B2 (en) Administration of citicoline to improve cognitive performance, attentional performance, and motor function
Cheng et al. Dissociation between recognition of familiar scenes and of faces in patients with very mild Alzheimer disease: an event-related potential study
Hansen et al. Neuropsychological assessment in multiple sclerosis
Jolles et al. The maastricht aging study
Rogelet et al. Posterior cortical atrophy: unusual feature of Alzheimer's disease
McCarthy et al. Memory, attention, and school problems in children with seizure disorders
Nestor et al. Distinct contribution of working memory and social comprehension failures in neuropsychological impairment in schizophrenia
Okada et al. Right hemispheric dominance and interhemispheric cooperation in gaze‐triggered reflexive shift of attention
Save et al. Caregiver's burden and psychosocial issues in alternating hemiplegia of childhood
Higgens Movement assessment
Leczycki et al. Persistent Neurological, Dissociative, and Amnestic Symptoms Following a Mild Traumatic Brain Injury in an Adolescent: A Complex Case of Conversion Disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)